Stockreport

InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum

InflaRx N.V.  (IFRX) 
Last inflarx n.v. earnings: 8/14 04:05 pm Check Earnings Report
PDF Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers JENA, Germany, June 13, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. ( [Read more]